TITLE

Adherence to Antiretroviral Therapy: How Much Is Enough?

AUTHOR(S)
Gulick, Roy M.
PUB. DATE
October 2006
SOURCE
Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p942
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study on the efficiency of the antiretroviral therapy. It has been stated that the development of effective antiretroviral therapy in the resulted to significant virologic suppression and immune reconstitution and resulted in dramatic reductions in HIV-related morbidity and mortality. For those patients taking antiretroviral therapy, maximal virologic suppression, maintenance or enhancement of immune function and prevention of HIV-related disease are their ultimate goals.
ACCESSION #
22251038

 

Related Articles

  • Incidence and Impact on Mortality of Severe Neurocognitive Disorders in Persons With and Without HIV Infection: A Danish Nationwide Cohort Study. Lescure, Françxois-Xavier; Omland, Lars Haukali; Engsig, Frederik Neess; Roed, Casper; Gerstoft, Jan; Pialoux, Gilles; Kronborg, Gitte; Larsen, Carsten Schade; Obel, Niels // Clinical Infectious Diseases;1/15/2011, Vol. 52 Issue 2, p235 

    Objective. The risk of neurocognitive disorders in human immunodefiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART) is controversial. We aimed to compare the incidence and impact on mortality of severe neurocognitive disorders (SNCDs) in HIV-infected...

  • Initiating Highly Active Antiretroviral Therapy with Newer Protease Inhibitors Is Associated with Better Survival Compared to First-Generation Protease Inhibitors or Nevirapine. Crane, Heidi M.; Van Rompaey, Stephen E.; Kitahata, Mari M. // AIDS Patient Care & STDs;Dec2007, Vol. 21 Issue 12, p920 

    The high prevalence of comorbidity among HIV-infected patients in care such as hepatitis C virus (HCV) coinfection and mental illness may contribute to increased toxicity and decreased adherence to highly active antiretroviral therapy (HAART). Newer HAART regimens have less toxicity and better...

  • HIV Infection�Associated Tuberculosis: The Epidemiology and the Response. Getahun, Haileyesus; Gunneberg, Christian; Granich, Reuben; Nunn, P0ul // Clinical Infectious Diseases;5/15/2010 Supplement 3, Vol. 50, pS201 

    Of the 33.2 million persons infected with human immunodeficiency virus (HIV), one-third are estimated to also be infected with Mycobacterium tuberculosis. In 2008, there were an estimated 1.4 million new cases of tuberculosis (TB) among persons with HIV infection, and TB accounted for 26% of...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • Five-Year Outcomes of the China National Free Antiretroviral Treatment Program.  // Annals of Internal Medicine;8/18/2009, Vol. 151 Issue 4, pI-42 

    The article presents a study on the rate of recovery of patients in the National Free Antiretroviral Treatment Program in China after five years. It notes that 48,785 patients with HIV were enrolled in the program under the highly active antiretroviral therapy. It mentions that after 6 months of...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2005, Vol. 19 Issue 10, p696 

    Reports several developments related to antiviral agents worldwide. Accounts on the reaction of HIV viral load to ritonavir-boosted atazanavir used as monotherapy; Analysis by Great Britain researchers on the benefit of highly active antiretroviral therapy when compared to no treatment in...

  • Immune recovery among HIV-infected patients in northwestern Tanzania after 2 years of anti-retroviral therapy use: a retrospective cohort study. MPONDO, BONAVENTURA C. T.; KABANGILA, RODRICK; EPHRAIM, LUCHERI; ERNEST, ALEX; KIDENYA, BENSON R. // Tanzania Journal of Health Research;Oct2015, Vol. 17 Issue 4, p1 

    Background: The use of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) is associated with significant and sustained decrease in the viral RNA levels that allows the immune system to recover. The extent of this immune recovery depends on the baseline CD4...

  • Oral Lesions of HIV Disease and HAART in Industrialized Countries. Hodgson, T. A.; Greenspan, D.; Greenspan, J. S. // Advances in Dental Research;Apr2006, Vol. 19 Issue 1, p57 

    The epidemiology of HIV-related oral disease in industrialized nations has evolved following the initial manifestations described in 1982. Studies from both the Americas and Europe report a decreased frequency of HIV-related oral manifestations of 10-50% following the introduction of HAART...

  • Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease. Moir, Susan; Malaspina, Angela; Ho, Jason; Wei Wang; DiPoto, Angela C.; O'Shea, Marie A.; Roby, Gregg; Mican, Joann M.; Kottilil, Shyam; Tae-Wook Chun; Proschan, Michael A.; Fauci, Anthony S. // Journal of Infectious Diseases;2/15/2008, Vol. 197 Issue 4, p572 

    Background. Untreated human immunodeficiency virus (HIV) disease leads to abnormalities in all major lymphocyte populations, including CD4+ T cells, CD8+ T cells, and B cells. However, little is known regarding the effect of antiretroviral therapy (ART)-induced decrease in HIV viremia on B cell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics